In addition, EGFR amplification (especially EGFRvIII) and TERT mutation have gained a key role in recognizing low-grade glioma IDH-wildtype, potentially associated with the worst prognosis and more aggressive behavior [3,4,5]. Here, EGFR is linked to central nervous system cancer.